BIOLASE, Inc. (NASDAQ:BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced the pricing of an underwritten public offering consisting of 16,453,569 shares of its common stock and pre-funded warrants to purchase 11,403,571 shares of common stock at a public offering price of $0.35 per share or $0.34 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.01 per share, are exercisable immediately, and will not expire until exercised. The offering is expected to close on January 12, 2023, subject to customary closing conditions.
Related Posts
Keybanc Upgrades Physicians Realty Trust to Overweight, Announces $17 Price Target
Keybanc analyst Todd Thomas upgrades Physicians Realty Trust (NYSE:DOC) from Sector Weight to Overweight and announces $17 price target.
Socket Mobile Receives Notice Of Allowance For U.S. Patent ‘APPLICATION-ASSISTED FRIENDLY PAIRING’
https://patentcenter.uspto.gov/#!/applications/17077904/ifw/docs
Tesla’s Huge Recall: Musk Led EV Company Recalls Over 1M Cars In Key Market China
A braking and acceleration defect prompted Tesla, Inc (NASDAQ:TSLA) to recall nearly every car it sold in China to prevent crashes and…